<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547049</url>
  </required_header>
  <id_info>
    <org_study_id>NFD-001</org_study_id>
    <nct_id>NCT04547049</nct_id>
  </id_info>
  <brief_title>A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies</brief_title>
  <official_title>An Open, Multi-center, Randomized Trial Comparing Haploidentical HSCTs From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open, multi-center, randomized trial comparing haploidentical HSCTs from young&#xD;
      non-first-degree and older first-degree donors in hematological malignancies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, multi-center, randomized trial comparing the clinical outcomes of&#xD;
      haploidentical HSCTs from young non-first-degree and older first-degree donors in&#xD;
      hematological malignancies. This study is indicated for patients with hematological&#xD;
      malignancies including ALL, AML, MDS and NHL who are eligible to haploidentical HSCTs. 2&#xD;
      groups of patients will be enrolled with 80 in each group. The clinical criteria including&#xD;
      survival, relapse, transplantation-related mortality will be monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of transplant-related nonrelapse mortality (NRM)</measure>
    <time_frame>2 years</time_frame>
    <description>All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of disease relapse or progression</measure>
    <time_frame>2 years</time_frame>
    <description>All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD-free, relapse-free survival (GRFS)</measure>
    <time_frame>2 years</time_frame>
    <description>All patients will be tracked from Day 0 to date of first objective disease progression, death from any cause, or last patient evaluation. Patients who have not progressed or died will be censored at the last date they were assessed and deemed free of relapse or progression.&#xD;
GRFS is defined as survival with no evidence of relapse/progression, grade III to IV aGVHD, and systemic therapy-requiring cGVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute grade II-IV GVHD</measure>
    <time_frame>2 years</time_frame>
    <description>Date of symptom onset, maximum clinical grade, and dates and types of treatment will be recorded. Dates of symptom onset of grade II or higher acute GVHD and grade III-IV acute GVHD will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of chronic GVHD</measure>
    <time_frame>2 years</time_frame>
    <description>Date of symptom onset, maximum clinical grade, and dates and types of treatment will be recorded. Dates of symptom onset of chronic GVHD and severe chronic GVHD will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Non-first-degree donor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each patient receive graft from a non-first degree donor aged â‰¤40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First-degree donor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each patients receive graft from a first-degree donor aged &gt;50</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>4 mg/m2/day administered IV day -10 through -9.</description>
    <arm_group_label>First-degree donor</arm_group_label>
    <arm_group_label>Non-first-degree donor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>3.2 mg/kg/day administered IV day -8 through -6.</description>
    <arm_group_label>First-degree donor</arm_group_label>
    <arm_group_label>Non-first-degree donor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>1.8 g/m2/day administered IV day -5 through -4.</description>
    <arm_group_label>First-degree donor</arm_group_label>
    <arm_group_label>Non-first-degree donor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Me-CCNU</intervention_name>
    <description>250mg/m2 once administered orally on day -3.</description>
    <arm_group_label>First-degree donor</arm_group_label>
    <arm_group_label>Non-first-degree donor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit antithymocyte globulin</intervention_name>
    <description>1.5mg/kg/day administered IV day -5 through -2.</description>
    <arm_group_label>First-degree donor</arm_group_label>
    <arm_group_label>Non-first-degree donor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic HSCT</intervention_name>
    <description>Day 0</description>
    <arm_group_label>First-degree donor</arm_group_label>
    <arm_group_label>Non-first-degree donor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin A</intervention_name>
    <description>2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.</description>
    <arm_group_label>First-degree donor</arm_group_label>
    <arm_group_label>Non-first-degree donor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.</description>
    <arm_group_label>First-degree donor</arm_group_label>
    <arm_group_label>Non-first-degree donor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.</description>
    <arm_group_label>First-degree donor</arm_group_label>
    <arm_group_label>Non-first-degree donor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient Inclusion Criteria:&#xD;
&#xD;
          -  Patient age 14-60 years&#xD;
&#xD;
          -  Absence of a suitable HLA identical related or unrelated hematopoietic stem cell donor&#xD;
&#xD;
          -  Absence of a suitable partially HLA-mismatched (haploidentical), first-degree related&#xD;
             donor aged between 18 and 50&#xD;
&#xD;
          -  Presence of both HLA haploidentical young non-first-degree (age â‰¤ 40) and older&#xD;
             first-degree (age &gt;50) donors&#xD;
&#xD;
        Eligible diagnoses:&#xD;
&#xD;
        AMLï¼ˆexcluding APLï¼‰ with at least one of the following:&#xD;
&#xD;
          -  median- or high- risk according to the WHO prognostic stratification system&#xD;
&#xD;
          -  failure to achieve CR after 2 cycles of induction chemotherapy&#xD;
&#xD;
          -  AML arising from MDS or a myeloproliferative disorder, or secondary AML&#xD;
&#xD;
          -  patients in CR2 or beyond, with &lt;5% bone marrow blasts before HSCT&#xD;
&#xD;
        ALL in remission, defined as &lt;5% bone marrow blasts morphologically&#xD;
&#xD;
        MDS with at least one of the following:&#xD;
&#xD;
          -  IPSS score of INT-2 or greater&#xD;
&#xD;
          -  IPSS score of INT-1 with life-threatening cytopenias, including those generally&#xD;
             requiring greater than weekly transfusions&#xD;
&#xD;
        NHLs (including diffuse large B-cell lymphoma, lymphoblastic lymphoma, Burkitt lymphoma,&#xD;
        peripheral T-cell lymphoma, and NK or NK-T cell lymphoma) which are relapsed/refractory OR&#xD;
        in CR2 or beyond&#xD;
&#xD;
          -  Adequate end-organ function&#xD;
&#xD;
          -  ECOG performance status &lt; 2&#xD;
&#xD;
          -  No other contraindications for HSCT&#xD;
&#xD;
          -  Signature of the informed consent&#xD;
&#xD;
        Patient Exclusion Criteria:&#xD;
&#xD;
          -  Availability of suitable HLA identical related or unrelated hematopoietic stem cell&#xD;
             donors&#xD;
&#xD;
          -  Availability of suitable partially HLA-mismatched (haploidentical), first-degree&#xD;
             related donor aged between 18 and 50&#xD;
&#xD;
          -  Presence of uncontrolled bacterial, viral, or fungal infection&#xD;
&#xD;
          -  Patients with severe heart, lung, liver and kidney insufficiency&#xD;
&#xD;
          -  HIV-positive patients&#xD;
&#xD;
          -  Women of childbearing potential who are pregnant (Î²-HCG+) or breast feeding&#xD;
&#xD;
          -  Patients with a psychiatric history&#xD;
&#xD;
          -  ECOG performance status â‰¥ 3&#xD;
&#xD;
          -  Patients with malignancies other than the primary disease&#xD;
&#xD;
          -  Refusal to sign the informed consent&#xD;
&#xD;
        Donor Inclusion Criteria:&#xD;
&#xD;
          -  The donor and recipient must be HLA haploidentical&#xD;
&#xD;
          -  Meets institutional selection criteria and medically fit to donate&#xD;
&#xD;
          -  Lack of recipient anti-donor HLA antibody&#xD;
&#xD;
        Donor Exclusion Criteria:&#xD;
&#xD;
          -  The donor and recipient are HLA identical&#xD;
&#xD;
          -  Has not donated blood products to recipient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Luo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Luo, MD</last_name>
    <phone>86-13666609126</phone>
    <email>luoyijr@zju.edu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yishan Ye, MD</last_name>
    <phone>86-18268068056</phone>
    <email>yeyishan@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haowen Xiao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Luo</last_name>
      <email>luoyijr@zju.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yishan Ye</last_name>
      <email>yeyishan@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Xu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianping Lan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinhua Hospital of Zhejiang University</name>
      <address>
        <city>Jinhua</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huixian Hu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo Hospital of Zhejiang University</name>
      <address>
        <city>Ningbo</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guifang Ouyang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated People's Hospital of Ningbo University</name>
      <address>
        <city>Ningbo</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Chen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Chen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Zhejiang University</investigator_affiliation>
    <investigator_full_name>Yi Luo</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

